000151683 001__ 151683
000151683 005__ 20251017144630.0
000151683 0247_ $$2doi$$a10.1016/j.clml.2021.07.022
000151683 0248_ $$2sideral$$a127469
000151683 037__ $$aART-2021-127469
000151683 041__ $$aeng
000151683 100__ $$aAbrisqueta P.
000151683 245__ $$aReal-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
000151683 260__ $$c2021
000151683 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151683 5203_ $$aBackground: Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of CLL patients receiving ibrutinib in routine clinical practice in Spain. Patients: Observational, retrospective, multicenter study in CLL patients who started single-agent ibrutinib as first-line treatment or at first or second relapse between January 2016 and January 2019. Results: A total of 269 patients were included (median age: 70.9 years; cardiovascular comorbidity: 55.4%, including hypertension [47.6%] and atrial fibrillation [AF] [7.1%]). Overall, 96.7% and 69% of patients underwent molecular testing for del(17p)/TP53 mutation and IGHV mutation status. High-risk genetic features included unmutated IGHV (79%) and del(17p)/TP53 mutation (first-line: 66.3%; second-line: 23.1%). Overall, 84 (31.2%) patients received ibrutinib as first-line treatment, and it was used as second- and third-line therapy in 121 (45.0%) and 64 (23.8%) patients. The median progression-free survival and overall survival were not reached irrespective of del(17p)/TP53, or unmutated IGHV. Common grade =3 adverse events were infections (12.2%) and bleeding (3%). Grade =3 AF occurred in 1.5% of patients. Conclusion: This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with clinical trials. Additionally, single-agent ibrutinib was well tolerated, with a low rate of cardiovascular events. This study also emphasized a high molecular testing rate of del(17p)/TP53 mutation and IGHV mutation status in clinical practice according to guideline recommendations.
000151683 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000151683 590__ $$a2.822$$b2021
000151683 591__ $$aHEMATOLOGY$$b56 / 78 = 0.718$$c2021$$dQ3$$eT3
000151683 591__ $$aONCOLOGY$$b192 / 245 = 0.784$$c2021$$dQ4$$eT3
000151683 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151683 700__ $$aLoscertales J.
000151683 700__ $$aTerol M.J.
000151683 700__ $$aRamírez Payer Á.
000151683 700__ $$aOrtiz M.
000151683 700__ $$aPérez I.
000151683 700__ $$aCuellar-García C.
000151683 700__ $$aFernández de la Mata M.
000151683 700__ $$aRodríguez A.
000151683 700__ $$aLario A.
000151683 700__ $$aDelgado J.
000151683 700__ $$aGodoy A.$$uUniversidad de Zaragoza
000151683 700__ $$aArguiñano Pérez J.M.
000151683 700__ $$aBerruezo M.J.
000151683 700__ $$aOliveira A.
000151683 700__ $$aHernández-Rivas J.-Á.
000151683 700__ $$aGarcía Malo M.D.
000151683 700__ $$aMedina Á.
000151683 700__ $$aGarcía Martin P.
000151683 700__ $$aOsorio S.
000151683 700__ $$aBaltasar P.
000151683 700__ $$aFernández-Zarzoso M.
000151683 700__ $$aMarco F.
000151683 700__ $$aVidal Manceñido M.J.
000151683 700__ $$aSmucler Simonovich A.
000151683 700__ $$aLópez Rubio M.
000151683 700__ $$aJarque I.
000151683 700__ $$aSuarez A.
000151683 700__ $$aFernández Álvarez R.
000151683 700__ $$aLancharro Anchel A.
000151683 700__ $$aRíos E.
000151683 700__ $$aLosada Castillo M.D.C.
000151683 700__ $$aPérez Persona E.
000151683 700__ $$aGarcía Muñoz R.
000151683 700__ $$aRamos R.
000151683 700__ $$aYáñez L.
000151683 700__ $$aBello J.L.
000151683 700__ $$aLoriente C.
000151683 700__ $$aAcha D.
000151683 700__ $$aVillanueva M.
000151683 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000151683 773__ $$g21, 12 (2021), e985-e999$$pCLINICAL LYMPHOMA MYELOMA & LEUKEMIA$$tCLINICAL LYMPHOMA MYELOMA & LEUKEMIA$$x2152-2650
000151683 8564_ $$s1019280$$uhttps://zaguan.unizar.es/record/151683/files/texto_completo.pdf$$yVersión publicada
000151683 8564_ $$s2608327$$uhttps://zaguan.unizar.es/record/151683/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151683 909CO $$ooai:zaguan.unizar.es:151683$$particulos$$pdriver
000151683 951__ $$a2025-10-17-14:25:56
000151683 980__ $$aARTICLE